NLRP3 and depressive symptom measurement: NLRP3 overactivation contributes to neurodegeneration across multiple conditions, such as depression, Alzheimer’s disease (AD), ischemic injury, and metabolic-associated cognitive decline, making it a major therapeutic target (6–9).